BioSpace News Archive

The late-stage study is part of an agreement struck between the company and the U.K. government last month that includes providing 60 million doses of the vaccine, should it be approved.

With help from investors, Monte Rosa expects the chemical libraries to comprise more than 10,000 structures designed for ubiquitin ligase reprogramming, a unique approach to destroy cancer-causing proteins that are not targetable by currently available therapies.

New York’s governor hinted he would delay distribution of a quickly approved vaccine until its safety and efficacy could be vetted by a panel of state scientists and researchers.

During his 2016 campaign, President Trump railed against high pharmaceutical prices, making promises to stand up for Americans who were being “slaughtered” on drug pricing. Now, the FDA has issued a final regulation intended to fulfill Trump’s promises.

A new study published in Nature on Sept. 24 suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.

Endo International’s subsidiary, Par Sterile Products, LLC, has agreed to provide fill-finish manufacturing services to Novavax for commercial distribution of the vaccine company’s nanoparticle COVID-19 vaccine candidate.

Even when a first vaccine is finally approved, much of the developing world currently stands to be left behind, as it was during the 2009 H1N1 pandemic.

PsychoGenics Inc. announces the appointment of Daniela Brunner, Ph.D. as Chief Innovation Officer, Geoffrey Varty, Ph.D. as Executive Vice President, Research Operations, and Leslie Street, Ph.D. as Vice President, Medicinal Chemistry. 

BioHiTech Global, Inc. (“BioHiTech” or the “Company”) (NASDAQ: BHTG), a sustainable technology and services company, announced today that the Company and the Hazleton Area School Distric

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: “The evolution of complement targeted therapies,” taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time